Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

• Forschungsstelle: INNOSUISSE
• Projektnummer: 13071.1 PFLS-LS
• Projekttitel Englisch: Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Kurzbeschreibung (Deutsch)

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Kurzbeschreibung (Englisch)

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Abstract (Deutsch)

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.

Abstract (Englisch)

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.